Aurora kinases in ovarian cancer. Perez Fidalgo J, Gambardella V, Pineda Merlo B, Burgues Gasion O, Piñero Sanchez O, Cervantes Ruiperez A. Esmo Open. 2020 Oct;5(5):e000718. doi: 10.1136/esmoopen-2020-000718. PMID: 33087400

Changing the education paradigm in oncology: ESO masterclass, 17 years of continuous success. Pavlidis N, Peccatori F, Aapro M, Rolfo C, Cervantes Ruiperez A, Stahel R, Eniu A, Cavalli F, Costa A. Critical Reviews in Oncology Hematology. 2020 Feb;146:102798. doi: 10.1016/j.critrevonc.2019.07.022. PMID: 31918958

Characterizing diversity in the tumor-immune microenvironment of distinct subclasses of gastroesophageal adenocarcinomas. Derks S, de Klerk L, Xu X, Fleitas Kanonnikoff T, Liu K, Liu Y, Dietlein F, Margolis C, Chiaravalli A, Da Silva A, Ogino S, Akarca F, Freeman G, Rodig S, Hornick J, VAN Allen E, Li B, Liu S, Thorsson V, Bass A. Annals of Oncology. 2020 Aug;31(8):1011-1020. doi: 10.1016/j.annonc.2020.04.011. PMID: 32387455

Chronological Age Interacts with the Circadian Melatonin Receptor 1B Gene Variation, Determining Fasting Glucose Concentrations in Mediterranean Populations. Additional Analyses on Type-2 Diabetes Risk. Sorli J, Barragan R, Coltell O, Portoles O, Pascual E, Ortega-Azorin C, Gonzalez J, Estruch R, Saiz C, Perez-Fidalgo A, Ordovas J, Corella D. Nutrients. 2020 Oct 29;12(11):3323. doi: 10.3390/nu12113323. PMID: 33138317

Clinical Case Presentation and Discussion During ESO-ESMO Masterclass: a 10-Year Interactive Educational Experience. Pavlidis N, Peccatori F, Aapro M, Cervantes Ruiperez A, Stahel R, Eniu A, Cavalli F, Costa A. Journal of Cancer Education. 2020 Apr 17. doi: 10.1007/s13187-020-01744-y. PMID: 32303982

Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL). Garcia Campelo R, Arrieta O, Massuti B, Rodriguez Abreu D, Ortega Granados AL, Majem M, Vicente D, Lianes P, Bosch Barrera J, Insa A, Domine M, Reguart N, Guirado M, Sala MA, Vazquez Estevez S, Bernabe Caro, R, Drozdowskyj A, Verdu A, Karachaliou N, Molina Vila MA, Rosell R. Lung Cancer. 2020 Dec;150:62-69. doi: 10.1016/j.lungcan.2020.09.018. PMID: 33070053

Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer – Results of the international randomized RAPIDO-trial (vol 147, pg 75, 2020). van der Valk MJM, Marijnen CAM, van Etten B, Dijkstra EA, Hilling DE, Kranenbarg EM, Putter H, Roodvoets AGH, Bahadoer RR, Fokstuen T, ten Tije AJ, Capdevila J, Hendriks MP, Edhemovic I, Cervantes A, de Groot Derk JA, Nilsson PJ, Glimelius B, van de Velde CJH, Hospers GAP. Radiotherapy and Oncology. 2020 Jun;147:e1. doi: 10.1016/j.radonc.2020.06.006. PMID: 32564889

Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer – Results of the international randomized RAPIDO-trial. van der Valk MJM, Marijnen CAM, van Etten B, Dijkstra EA, Hilling DE, Kranenbarg EM, Putter H, Roodvoets AGH, Bahadoer RR, Fokstuen T, ten Tije AJ, Capdevila J, Hendriks MP, Edhemovic I, Cervantes A, de Groot DJA, Nilsson PJ, Glimelius B, van de Velde CJH, Hospers GAP. Radiotherapy and Oncology. 2020 Jun;147:75-83. doi: 10.1016/j.radonc.2020.03.011. PMID: 32240909

Computational evaluation and in vitro validation of new Epidermal Growth Factor Receptor inhibitors. Gomez-Ganau S, Castillo Aliaga J, Cervantes Ruiperez A, de Julian Ortiz J, Gozalbes R. Current Topics in Medicinal Chemistry. 2020;20(18):1628-1639. doi: 10.2174/1568026620666200603122726. PMID: 32493189

Detection of postoperative plasma circulating tumour DNA and lack of CDX2 expression as markers of recurrence in patients with localised colon cancer. Tarazona Llavero N, Gimeno Valiente F, Gambardella V, Huerta Alvaro M, Roselló Keränen S, Zúñiga Trejos S, Calon A, Carbonell Asins J, Fontana E, Martínez Ciarpaglini M, Eason K, Rentero Garrido P, Fleitas Kanonnikoff T, Papaccio F, Moro Valdezate D, Nyamundanda G, Castillo Aliaga J, Espí Macias A, Sadanandam A, Roda Perez D, Cervantes Ruiperez A. Esmo Open. 2020 Sep;5(5):e000847. doi: 10.1136/esmoopen-2020-000847. PMID: 32967918

Diagnostic delay and outcome in immunocompetent patients with primary central nervous system lymphoma in Spain: a multicentric study. Velasco R, Mercadal S, Vidal N, Alana M, Barcelo M, Ibanez-Julia M, Bobillo S, Caldu Agud R, Garcia Molina E, Martinez P, Cacabelos P, Muntanola A, Garcia-Catalan G, Sancho J, Camro I, Lado T, Erro M, Gomez-Vicente L, Salar A, Caballero A, Sole-Rodriguez M, Gallego Perez-Larraya J, Huertas N, Estela J, Baron M, Barbero-Bordallo N, Encuentra M, Dlouhy I, Bruna J, Graus F, Bruixola Campos G, GELTAMO & GENOSEN Grp. Journal of Neuro-Oncology. 2020 Jul;148(3):545-554. doi: 10.1007/s11060-020-03547-z. PMID: 32524392

Easy One-Step Amplification and Labeling Procedure for Copy Number Variation Detection. Blesa Luján S, Olivares Gazquez M, Alic A, Serrano Alcalá A, Lendinez Tortajada V, Gonzalez Albert V, Olivares Ordoñez L, Martinez Hervas S, Juanes Tébar J, Marin P, Real Collado J, Navarro Cubells B, García García A, Chaves Martínez F, Ivorra C. Clinical Chemistry. 2020 Mar 1;66(3):463-473. doi: 10.1093/clinchem/hvaa002. PMID: 32068788

Editorial debate: Challenges we oncologists, working within a universal healthcare system, have to face in these hard times. Cervantes Ruiperez A. Esmo Open. 2020 May;5(3):e000800. doi: 10.1136/esmoopen-2020-000800. PMID: 32366509

Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer. Smyth L, Piha-Paul S, Won H, Schram A, Saura C, Loi S, Lu J, Shapiro G, Juric D, Mayer I, Arteaga C, de la Fuente M, Brufksy A, Spanggaard I, Mau-Sorensen M, Arnedos M, Moreno V, Boni V, Sohn J, Schwartzberg L, Gonzalez-Farre X, Cervantes Ruiperez A, Bidard F, Gorelick A, Lanman R, Nagy R, Ulaner G, Chandarlapaty S, Jhaveri K, Gavrila E, Zimel C, Selcuklu S, Melcer M, Samoila A, Cai Y, Scaltriti M, Mann G, Xu F, Eli L, Dujka M, Lalani A, Bryce R, Baselga J, Taylor B, Solit D, Meric-Bernstam F, Hyman D. Cancer Discovery. 2020 Feb;10(2):198-213. doi: 10.1158/2159-8290.CD-19-0966. PMID: 31806627

Endometriosis-associated ovarian carcinomas: insights into pathogenesis, diagnostics, and therapeutic targets-a narrative review. Samartzis E, Labidi-Galy S, Moschetta M, Uccello M, Kalaitzopoulos D, Perez-Fidalgo J, Boussios S. Annals of Translational Medicine. 2020 Dec;8(24):1712. doi: 10.21037/atm-20-3022a. PMID: 33490224

EPDR1 up-regulation in human colorectal cancer is related to staging and favours cell proliferation and invasiveness. Gimeno Valiente F, Riffo Campos Á, Ayala Gallego G, Tarazona Llavero N, Gambardella V, Rodriguez F, Huerta Alvaro M, Martínez Ciarpaglini M, Monton Bueno J, Roselló Keränen S, Roda Perez D, Cervantes Ruiperez A, Franco Vera L, Lopez Rodas G, Castillo Aliaga J. Scientific Reports. 2020 Feb 28;10(1):3723. doi: 10.1038/s41598-020-60476-7. PMID: 32111877

Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter «SLAVE» Study. Parisi A, Cortellini A, Cannita K, Venditti O, Camarda F, Calegari M, Salvatore L, Tortora G, Rossini D, Germani M, Boccaccino A, Dell’aquila E, Fulgenzi C, Santini D, Tursi M, Tinari N, Marino P, Lombardi P, Roselló Keränen S, Huerta Alvaro M, Zurlo I, Corsi D, Emiliani A, Zanaletti N, Troiani T, Vitale P, Giampieri R, Merloni F, Occhipinti M, Marchetti P, Roberto M, Mazzuca F, Ghidini M, Indini A, Garajova I, Zoratto F, Monache S, Porzio G, Ficorella C. Cancers. 2020 May 16;12(5):1259. doi: 10.3390/cancers12051259. PMID: 32429380

How we treat metastatic colorectal cáncer. De Falco V, Napolitano S, Rosello S, Huerta M, Cervantes A, Ciardiello F, Troiani T. Esmo Open. 2020 Aug;4(Suppl 2):e000813. doi: 10.1136/esmoopen-2020-000813. PMID: 32817137

Impact of perioperative transfusions and sepsis on long-term oncologic outcomes after curative colon cancer resection. A retrospective analysis of a prospective database. Baguena G, Pellino G, Frasson M, Escrig J, Marinello F, Espí Macias A, Garcia-Granero A, Roselló Keränen S, Cervantes Ruiperez A, Garcia-Granero E. Gastroenterologia y Hepatologia. 2020 Feb;43(2):63-72. doi: 10.1016/j.gastrohep.2019.07.005. PMID: 31918857

In the literature: April 2020. Gambardella V, Roda D, Tarazona N, Cervantes A. Esmo Open. 2020 Apr;5(2):e000749. doi: 10.1136/esmoopen-2020-000749. PMID: 32317263

In the literature: August 2020. Gambardella V, Cejalvo J, Tarazona N, Cervantes A. Esmo Open. 2020 Aug;5(4):e000909. doi: 10.1136/esmoopen-2020-000909. PMID: 32817070

In the literature: December 2019. Gambardella V, Insa A, Cejalvo J, Cervantes A. Esmo Open. 2020 Jan;5(1):e000642. doi: 10.1136/esmoopen-2019-000642. PMID: 31958287

In the literature: February 2020. Roda D, Gambardella V, Cejalvo JM, Cervantes A. 2020 Feb;5(1):e000680. doi: 10.1136/esmoopen-2020-000680. PMID: 32079625

In the literature: June 2020. Roda D, Gambardella V, Cejalvo JM, Cervantes A. Esmo Open. 2020 Jul;5(4):e000832. doi: 10.1136/esmoopen-2020-000832. PMID: 32641355

In the literature: October 2020. Gambardella V, Bruixola Campos G, Alfaro Cervelló C, Cervantes Ruiperez A. Esmo Open. 2020 Oct;5(5):e001048. doi: 10.1136/esmoopen-2020-001048. PMID: 33037034

Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study. Guo C, Chenard-Poiriet M, Roda D, de Miguel M, Harris S, Candilejo I, Sriskandarajah P, Xu W, Scaranti M, Constantinidou A, King J, Parmar M, Turner A, Carreira S, Riisnaes R, Finneran L, Hall E, Ishikawa Y, Nakai K, Tunariu N, Basu B, Kaiser M, Lopez J, Minchom A, de Bono J, Banerji U. The Lancet Oncology. 2020 Nov;21(11):1478-1488. doi: 10.1016/S1470-2045(20)30464-2. PMID: 33128873

Intrasinusoidal HHV8-EBV-Positive Large B-Cell Lymphoma With Features of Germinotropic Lymphoproliferative Disorder. Martínez Ciarpaglini M, Valkov A, Hurtado M, Agusti Martinez J, Malave G, Ferrandez Izquierdo A. International Journal of Surgical Pathology. 2020 Oct;28(7):804-811. doi: 10.1177/1066896920921238. PMID: 32423260

JSCO-ESMO-ASCO-JSMO-TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions. Yoshino T, Pentheroudakis G, Mishima S, Overman M, Yeh K, Baba E, Naito Y, Calvo F, Saxena A, Chen L, Takeda M, Cervantes Ruiperez A, Taniguchi H, Yoshida K, Kodera Y, Kitagawa Y, Tabernero J, Burris H, Douillard J. Annals of Oncology. 2020 Jul;31(7):861-872. doi: 10.1016/j.annonc.2020.03.299. PMID: 32272210

Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group. Remon J, Nadal E, Domine M, Ruffinelli J, Garcia Y, Pardo JC, Lopez R, Cilleruelo A, Garcia Campelo R, Martin P, Juan O, Gonzalez Larriba JL, Provencio M, Olmedo E, Ponce S, Cumplido D, Barenys C, Majem M, Massutti B, Rodriguez Abreu D, Porta R, Sala MA, Martinez Kareaga M, Lianes P, Reguart N. Lung Cancer. 2020 Sep;147:83-90. doi: 10.1016/j.lungcan.2020.06.034. PMID: 32682189

Managing cancer patients during the COVID-19 pandemic: An ESMO Interdisciplinary Expert Consensus. Curigliano G, Banerjee S, Cervantes Ruiperez A, Garassino M, Garrido P, Girard N, Haanen J, Jordan K, Lordick F, Machiels J, Michielin O, Peters S, Tabernero J, Douillard J, Pentheroudakis G, all Voting Panel members. Annals of Oncology. 2020 Oct;31(10):1320-1335. doi: 10.1016/j.annonc.2020.07.010. PMID: 32745693

Melanoma of Unknown Primary: New Perspectives for an Old Story. Boussios S, Rassy E, Samartzis E, Moschetta M, Sheriff M, Perez-Fidalgo J, Pavlidis N. Critical reviews in oncology/hematology. 2020 Dec 28;158:103208. doi: 10.1016/j.critrevonc.2020.103208. PMID: 33383207

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Provencio M, Nadal E, Insa A, Garcia-Campelo M, Casal-Rubio J, Domine M, Majem M, Rodriguez-Abreu D, Martinez-Marti A, Carpeno J, Cobo M, Vivanco G, Del Barco E, Caro R, Vinolas N, Aranda I, Viteri S, Pereira E, Royuela A, Casarrubios M, Anton C, Parra E, Wistuba I, Calvo V, Laza-Briviesca R, Romero A, Massuti B, Cruz-Bermudez A. Lancet Oncology. 2020 Nov;21(11):1413-1422. doi: 10.1016/S1470-2045(20)30453-8. PMID: 32979984

Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer. Papaccio F, Rosello S, Huerta M, Gambardella V, Tarazona N, Fleitas T, Roda D, Cervantes A. Cancers. 2020 Dec 3;12(12):E3611. doi: 10.3390/cancers12123611. PMID: 33287114

Neoadjuvant treatment for locally advanced unresectable and borderline resectable pancreatic cancer: oncological outcomes at a single academic centre. Rosello S, Pizzo C, Huerta M, Munoz E, Aliaga R, Vera A, Alfaro-Cervello C, Jorda E, Garces-Albir M, Roda D, Dorcaratto D, Tarazona N, Torondel S, Guijarro J, Sanchiz V, Gambardella V, Fleitas-Kanonnikoff T, Lluch P, Pascual I, Ferrandez A, Sabater L, Cervantes A. Esmo Open. 2020 Nov;5(6):e000929. doi: 10.1136/esmoopen-2020-000929. PMID: 33229503

New Guidelines for optimal patient care with localized colon cancer: recommending what is proven, but also watching what research is bringing. Tarazona Llavero N, Roda Perez D, Roselló Keränen S, Huerta Alvaro M, Cervantes Ruiperez A. Annals of Oncology. 2020 Oct;31(10):1287-1288. doi: 10.1016/j.annonc.2020.07.012. PMID: 32710931

NOTCH signalling in ovarian cancer angiogénesis. Perez-Fidalgo J, Ortega B, Simon S, Samartzis E, Boussios S. Annals of Translational Medicine. 2020 Dec;8(24):1705. doi: 10.21037/atm-20-4497. PMID: 33490217

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. Chen L, Martinelli E, Cheng A, Pentheroudakis G, Qin S, Bhattacharyya G, Ikeda M, Lim H, Ho G, Choo S, Ren Z, Malhotra H, Ueno M, Ryoo B, Kiang T, Tai D, Vogel A, Cervantes Ruiperez A, Lu S, Yen C, Huang Y, Chen S, Hsu C, Shen Y, Tabernero J, Yen Y, Hsu C, Yoshino T, Douillard J. Annals of Oncology. 2020 Mar;31(3):334-351. doi: 10.1016/j.annonc.2019.12.001. PMID: 32067677

Personalized Medicine: Recent Progress in Cancer Therapy. Gambardella V, Tarazona Llavero N, Cejalvo Andujar J, Lombardi P, Huerta Alvaro M, Roselló Keränen S, Fleitas Kanonnikoff T, Roda Perez D, Cervantes Ruiperez A. Cancers. 2020 Apr 19;12(4):1009. doi: 10.3390/cancers12041009. PMID: 32325878

Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cáncer. Voss MH, Gordon MS, Mita M, Rini B, Makker V, Macarulla T, Smith DC, Cervantes A, Puzanov I, Pili R, Wang D, Jalal S, Pant S, Patel MR, Neuwirth RL, Enke A, Shou Y, Sedarati F, Faller DV, Burris HA. British Journal of Cancer. 2020 Nov;123(11):1590-1598. doi: 10.1038/s41416-020-01041-x. PMID: 32913286

Phase I trial of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1/2 and non-BRCA1/2 mutant cancers. Yap T, Kristeleit R, Michalarea V, Pettitt S, Lim J, Carreira S, Roda Perez D, Miller R, Riisnaes R, Miranda S, Figueiredo I, Nava Rodrigues D, Ward S, Matthews R, Parmar M, Turner A, Tunariu N, Chopra N, Gevensleben H, Turner N, Ruddle R, Raynaud F, Decordova S, Swales K, Finneran L, Hall E, Rugman P, Lindemann J, Foxley A, Lord C, Banerji U, Plummer R, Basu B, Lopez J, Drew Y, de Bono J.Cancer Discovery. 2020 Oct;10(10):1528-1543. doi: 10.1158/2159-8290.CD-20-0163.PMID: 32532747

Precision Medicine to Treat Advanced Gastroesophageal Adenocarcinoma: A Work in Progress. Gambardella V, Fleitas Kanonnikoff T, Tarazona Llavero N, Papaccio F, Huerta Alvaro M, Roselló Keränen S, Gimeno Valiente F, Roda Perez D, Cervantes Ruiperez A. Journal of Clinical Medicine. 2020 Sep 22;9(9):3049. doi: 10.3390/jcm9093049. PMID: 32971757

Pregnancy After Breast Cancer in Patients With Germline BRCA Mutations. Lambertini M, Ameye L, Hamy A, Zingarello A, Poorvu P, Carrasco E, Grinshpun A, Han S, Rousset-Jablonski C, Ferrari A, Paluch-Shimon S, Cortesi L, Senechal C, Miolo G, Pogoda K, Perez Fidalgo J, De Marchis L, Ponzone R, Livraghi L, Estevez-Diz M, Villarreal-Garza C, Dieci M, Clatot F, Berliere M, Graffeo R, Teixeira L, Cordoba O, Sonnenblick A, Luna Pais H, Ignatiadis M, Paesmans M, Partridge A, Caron O, Saule C, Del Mastro L, Peccatori F, Azim H. Journal of Clinical Oncology. 2020 Sep 10;38(26):3012-3023. doi: 10.1200/JCO.19.02399. PMID: 32673153

Sun exposure and PDZK1 genotype modulate PDZK1 gene expression in normal skin. Hernando B, Ibarrola Villava M, Oltra Sanchis S, Valcuende-Cavero F, Pitarch G, Mahiques L, Ribas G, Martinez-Cadenas C. Photodermatology Photoimmunology & Photomedicine. 2020 Jan;36(1):70-72. doi: 10.1111/phpp.12508. PMID: 31444921

Systemic treatment of newly diagnosed advanced epithelial ovarian cancer: From chemotherapy to precision medicine. Perez-Fidalgo J, Grau F, Farinas L, Oaknin A. Critical reviews in oncology/hematology. 2020 Dec 31;158:103209. doi: 10.1016/j.critrevonc.2020.103209. PMID: 33388455

The 2017 Assisi Think Tank Meeting on rectal cancer: A positioning paper. Valentini V, Marijnen C, Beets G, Bujko K, De Bari B, Cervantes Ruiperez A, Chiloiro G, Coco C, Gambacorta M, Glynne-Jones R, Haustermans K, Meldolesi E, Peters F, Rodel C, Rutten H, van de Velde C, Aristei C. Radiotherapy and Oncology. 2020 Jan;142:6-16. doi: 10.1016/j.radonc.2019.07.001. PMID: 31431374

The actual management of colorectal liver metastases. Pérez Santiago L, Dorcaratto D, Garces Albir M, Muñoz Forner E, Huerta Alvaro M, Roselló Keränen S, Sabater Orti L. Minerva Chirurgica. 2020 Oct;75(5):328-344. doi: 10.23736/S0026-4733.20.08436-9. PMID: 32773753

The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC). Bendell J, Sauri T, Cubillo Gracian A, Alvarez R, Lopez-Lopez C, Garcia-Alfonso P, Hussein M, Limon Miron M, Cervantes Ruiperez A, Montagut C, Santos Vivas C, Bessudo A, Plezia P, Moons V, Andel J, Bennouna J, van der Westhuizen A, Samuel L, Rossomanno S, Boetsch C, Lahr A, Franjkovic I, Heil F, Lechner K, Krieter O, Hurwitz H, McCAVE Study Grp. Oncologist. 2020 Mar;25(3):e451-e459. doi: 10.1634/theoncologist.2019-0291. PMID: 32162804

The role of tumor-associated macrophages in gastric cancer development and their potential as a therapeutic target. Gambardella V, Castillo Aliaga J, Tarazona Llavero N, Gimeno Valiente F, Martínez Ciarpaglini M, Cabeza Segura M, Roselló Keränen S, Roda Perez D, Huerta Alvaro M, Cervantes Ruiperez A, Fleitas Kanonnikoff T. Cancer Treatment Reviews. 2020 Jun;86:102015. doi: 10.1016/j.ctrv.2020.102015. PMID: 32248000

Trifluridine/Tipiracil in earlier lines of chemotherapy for advanced colorectal cancer. Roda Perez D, Roselló Keränen S, Huerta Alvaro M, Cervantes Ruiperez A. Annals of Oncology. 2020 Sep;31(9):1097-1098. doi: 10.1016/j.annonc.2020.05.030. PMID: 32544547

Unexpected finding of iIntravascular large B-cell lymphoma by a skin biopsy. Guillen-Climent S, Garcia-Vazquez A, Martinez-Ciarpaglini C. Medicina Clinica. 2020 Sep 17;S0025-7753(20)30465-6. doi: 10.1016/j.medcli.2020.04.051. PMID: 32951879

Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Non-Small Cell Lung Carcinoma Patients: the ROSING Study. Conde E, Hernandez S, Martinez R, Angulo B, De Castro J, Collazo-Lorduy A, Jimenez B, Muriel A, Mate JL, Moran T, Aranda I, Massuti B, Rojo F, Domine M, Sansano I, Garcia F, Felip E, Mancheño N, Juan O, Sanz J, Gonzalez-Larriba JL, Atienza-Cuevas L, Arriola-Arellano E, Abdulkader I, Garcia-Gonzalez J, Camacho C, Rodriguez-Abreu D, Teixido C, Reguart N, Gonzalez-Piñeiro A, Lazaro-Quintela M, Lozano MD, Gurpide A, Gomez-Roman J, Lopez-Brea M, Pijuan L, Salido M, Arriola E, Company A, Insa A, Esteban-Rodriguez I, Saiz M, Azkona E, Alvarez R, Artal A, Plaza ML, Aguiar D, Enguita AB, Benito A, Paz-Ares L, Garrido P, Lopez-Rios F. Journal of Thoracic Oncology. 2019 Dec;14(12):2120-2132. doi: 10.1016/j.jtho.2019.07.005. PMID: 31349061

Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Eng C, Kim TW, Bendell J, Argilés G, Tebbutt NC, Di Bartolomeo M, Falcone A, Fakih M, Kozloff M, Segal NH, Sobrero A, Yan Y, Chang I, Uyei A, Roberts L, Ciardiello F; IMblaze370 Investigators. Lancet Oncology. 2019 Jun;20(6):849-861. doi: 10.1016/S1470-2045(19)30027-0. PMID: 31003911

BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population. Turner NC, Alarcón E, Armstrong AC, Philco M, López Chuken YA, Sablin MP, Tamura K, Gómez Villanueva A, Pérez-Fidalgo JA, Cheung SYA, Corcoran C, Cullberg M, Davies BR, de Bruin EC, Foxley A, Lindemann JPO, Maudsley R, Moschetta M, Outhwaite E, Pass M, Rugman P, Schiavon G, Oliveira M. Annals of Oncology. 2019 May 1;30(5):774-780. doi: 10.1093/annonc/mdz086. PMID: 30860570

Combination of KIR2DS4 and Fc gamma RII alpha polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer (vol 9, 2589, 2019). Borrero-Palacios A, Cebrián A, Gómez Del Pulgar MT, García-Carbonero R, Garcia-Alfonso P, Aranda E, Elez E, López-López R, Cervantes A, Valladares M, Nadal C, Viéitez JM, Guillén-Ponce C, Rodríguez J, Hernández I, García JL, Vega-Bravo R, Puime-Otin A, Martínez-Useros J, Del Puerto-Nevado L, Rincón R, Rodríguez-Remírez M, Rojo F, García-Foncillas J. Scientific Reports. 2019 May 17;9(1):7706. doi: 10.1038/s41598-019-43809-z. PMID: 31097738

Combination of KIR2DS4 and Fc gamma RIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cáncer. Borrero-Palacios A, Cebrián A, Gómez Del Pulgar MT, García-Carbonero R, Garcia-Alfonso P, Aranda E, Elez E, López-López R, Cervantes A, Valladares M, Nadal C, Viéitez JM, Guillén-Ponce C, Rodríguez J, Hernández I, García JL, Vega-Bravo R, Puime-Otin A, Martínez-Useros J, Del Puerto-Nevado L, Rincón R, Rodríguez-Remírez M, Rojo F, García-Foncillas J. Scientific Reports. 2019 Feb 22;9(1):2589. doi: 10.1038/s41598-019-39291-2. PMID: 30796344

Context matters-consensus molecular subtypes of colorectal cancer as biomarkers for clinical trials. Fontana E, Eason K, Cervantes A, Salazar R, Sadanandam A. Annals of oncology. 2019 Apr 1;30(4):520-527. doi: 10.1093/annonc/mdz052. PMID: 30796810

CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC. Becker JH, Gao Y, Soucheray M, Pulido I, Kikuchi E, Rodríguez ML, Gandhi R, Lafuente-Sanchis A, Aupí M, Alcácer Fernández-Coronado J, Martín-Martorell P, Cremades A, Galbis-Caravajal JM, Alcácer J, Christensen CL, Simms P, Hess A, Asahina H, Kahle MP, Al-Shahrour F, Borgia JA, Lahoz A, Insa A, Juan O, Jänne PA, Wong KK, Carretero J, Shimamura T. Cancer Research. 2019 Sep 1;79(17):4439-4452. doi: 10.1158/0008-5472.CAN-19-0024. PMID: 31273063

Definition of the Rectum: An International, Expert-based Delphi Consensus. DʼSouza N, de Neree Tot Babberich MPM, d’Hoore A, Tiret E, Xynos E, Beets-Tan RGH, Nagtegaal ID, Blomqvist L, Holm T, Glimelius B, Lacy A, Cervantes A, Glynne-Jones R, West NP, Perez RO, Quadros C, Lee KY, Madiba TE, Wexner SD, Garcia-Aguilar J, Sahani D, Moran B, Tekkis P, Rutten HJ, Tanis PJ, Wiggers T, Brown G. Annals of Surgery. 2019 Dec;270(6):955-959. doi: 10.1097/SLA.0000000000003251. PMID: 30973385

Educational needs in gastrointestinal cancer: a consensus position paper from the ESMO Gastrointestinal Cancer Faculty. Lordick F, Obermannova R, Vola D, Douillard J, Mcgregor K, Van Cutsem E, Tabernero J, Ciardiello F, Cervantes Ruiperez A. Esmo Open. 2019 Jul 5;4(3):e000533. doi: 10.1136/esmoopen-2019-000533. PMID: 31354964

ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors (vol 24, pg 2517, 2018). Guerrero-Zotano AL, Stricker TP, Formisano L, Hutchinson KE, Stover DG, Lee KM, Schwarz LJ, Giltnane JM, Estrada MV, Jansen VM, Servetto A, Gavilá J, Perez-Fidalgo JA, Lluch A, Llombart-Cussac A, Bayar MA, Michiels S, André F, Arnedos M, Guillem V, Ruiz-Simon A, Arteaga CL. Clinical Cancer Research. 2019 Feb 15;25(4):1431. doi: 10.1158/1078-0432.CCR-18-4270. PMID: 30770490

Exploratory findings from a prematurely closed international, multicentre, academic trial: RAVELLO, a phase III study of regorafenib versus placebo as maintenance therapy after first-line treatment in RAS wild-type metastatic colorectal cáncer. Cardone C, Martinelli E, Troiani T, Sforza V, Avallone A, Nappi A, Montesarchio V, Andreozzi F, Biglietto M, Calabrese F, Bordonaro R, Cordio S, Bregni G, Febbraro A, Garcia-Carbonero R, Feliu J, Cervantes Ruiperez A, Ciardiello F. Esmo Open. 2019 Aug 16;4(4):e000519. doi: 10.1136/esmoopen-2019-000519. PMID: 31555481

Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer. González Martín A, Oza AM, Embleton AC, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Bertrand MA, Beale P, Cervantes A, Kent E, Kaplan RS, Parmar MKB, Scotto N, Perren TJ; ICON7 investigators. Gynecologic Oncology. 2019 Jan;152(1):53-60. doi: 10.1016/j.ygyno.2018.08.036. PMID: 30449719

Extra-Adrenal Adult Neuroblastoma With Aberrant Germ Cell Marker Expression: Maturation After Chemotherapy as an Important Clue to a Challenging Diagnosis. Martinez-Ciarpaglini C, Machado I, Yoshida A, Nieto G, Berbegall AP, Blanquer-Maceíras MT, Noguera R, Ferrández A, Navarro S. International Journal of Surgical Pathology. 2019 Aug;27(5):568-573. doi: 10.1177/1066896919835945. PMID: 30907195

Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (vol 29, pg iv238, 2018). Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, Nault JC, Neumann U, Ricke J, Sangro B, Schirmacher P, Verslype C, Zech CJ, Arnold D, Martinelli E. Annals of Oncology. 2019 May 1;30(5):871-873. doi: 10.1093/annonc/mdy510. PMID: 30715202

Hereditary gastrointestinal cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Stjepanovic N, Moreira L, Carneiro F, Balaguer F, Cervantes A, Balmaña J, Martinelli E; ESMO Guidelines Committee. Annals of Oncology. 2019 Oct 1;30(10):1558-1571. doi: 10.1093/annonc/mdz233. PMID: 31378807

Improving tumor budding evaluation in colon cancer by extending the assessment area in colectomy specimen. Martinez-Ciarpaglini C, Fernandez-Sellers C, Tarazona N, Roselló S, Huerta M, Roda D, Mongort C, Ferrández A, Navarro S, Cervantes A. Histopathology. 2019 Oct;75(4):517-525. doi: 10.1111/his.13900. PMID: 31081121

In the literature: August 2018. Gambardella V, Bruixola Campos G, Papaccio F, Cejalvo Andujar J, Cervantes Ruiperez A. Esmo Open. 2019 Jul 21;4(4):e000563. doi: 10.1136/esmoopen-2019-000563. PMID: 31423340

In the literature: February 2019. Insa Molla A, Gambardella V, Cervantes Ruiperez A. Esmo Open. 2019 Feb 13;4(1):e000490. doi: 10.1136/esmoopen-2019-000490. PMID: 30962957

Low miR200c expression in tumor budding of invasive front predicts worse survival in patients with localized colon cancer and is related to PD-L1 overexpression. Martinez-Ciarpaglini C, Oltra S, Roselló S, Roda D, Mongort C, Carrasco F, Gonzalez J, Santonja F, Tarazona N, Huerta M, Espí A, Ribas G, Ferrández A, Navarro S, Cervantes A. Modern Pathology. 2019 Feb;32(2):306-313. doi: 10.1038/s41379-018-0124-5. PMID: 30206410

MC1R variants in childhood and adolescent melanoma: a retrospective pooled analysis of a multicentre cohort. Pellegrini C, Botta F, Massi D, Martorelli C, Facchetti F, Gandini S, Maisonneuve P, Avril M, Demenais F, Bressac-de Paillerets B, Hoiom V, Cust A, Anton-Culver H, Gruber S, Gallagher R, Marrett L, Zanetti R, Dwyer T, Thomas N, Begg C, Berwick M, Puig S, Potrony M, Nagore E, Ghiorzo P, Menin C, Manganoni A, Rodolfo M, Brugnara S, Passoni E, Sekulovic L, Baldini F, Guida G, Stratigos A, Ozdemir F, Ayala F, Fernandez-de-Misa R, Quaglino P, RIBAS DESPUIG G, Romanini A, Migliano E, Stanganelli I, Kanetsky P, Pizzichetta M, García-Borrón J, Nan H, Landi M, Little J, Newton-Bishop J, Sera F, Fargnoli M, Raimondi S, IMI Study Group, GEM Study Group, M-SKIP Study Group. Lancet Child & Adolescent Health. 2019 May;3(5):332-342. doi: 10.1016/S2352-4642(19)30005-7. PMID: 30872112

miR302a and 122 are deregulated in small extracellular vesicles from ARPE-19 cells cultured with H2O2. Oltra M, Vidal-Gil L, Maisto R, Oltra SS, Romero FJ, Sancho-Pelluz J, Barcia JM. Scientific Reports. 2019 Nov 29;9(1):17954. doi: 10.1038/s41598-019-54373-x. PMID: 31784665

Molecular profile in Paraguayan colorectal cancer patients, towards to a precision medicine strategy. Fleitas-Kanonnikoff T, Martinez-Ciarpaglini C, Ayala J, Gauna C, Denis R, Yoffe I, Sforza S, Martínez MT, Pomata A, Ibarrola-Villava M, Arevshatyan S, Burriel V, Boscá D, Pastor O, Ferrer-Martinez A, Carrasco F, Mongort C, Navarro S, Ribas G, Cervantes A. Cancer Medicine. 2019 Jun;8(6):3120-3130. doi: 10.1002/cam4.2191. PMID: 31059199

Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors. Bahleda R, Italiano A, Hierro C, Mita A, Cervantes A, Chan N, Awad M, Calvo E, Moreno V, Govindan R, Spira A, Gonzalez M, Zhong B, Santiago-Walker A, Poggesi I, Parekh T, Xie H, Infante J, Tabernero J. Clinical Cancer Research. 2019 Aug 15;25(16):4888-4897. doi: 10.1158/1078-0432.CCR-18-3334. PMID: 31088831

NRF2 through RPS6 Activation Is Related to Anti-HER2 Drug Resistance in HER2 -Amplified Gastric Cancer. Gambardella V, Gimeno-Valiente F, Tarazona N, Martinez-Ciarpaglini C, Roda D, Fleitas T, Tolosa P, Cejalvo JM, Huerta M, Roselló S, Castillo J, Cervantes A. Clinical Cancer Research. 2019 Mar 1;25(5):1639-1649. doi: 10.1158/1078-0432.CCR-18-242. PMID: 30504425

Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial. Adamo B, Bellet M, Paré L, Pascual T, Vidal M, Pérez Fidalgo JA, Blanch S, Martinez N, Murillo L, Gómez-Pardo P, López-González A, Amillano K, Canes J, Galván P, González-Farré B, González X, Villagrasa P, Ciruelos E, Prat A. Breast Cancer Research. 2019 Sep 18;21(1):108. doi: 10.1186/s13058-019-1195-z. PMID: 31533777

Oral vinorelbine versus etoposide with cisplatin and chemo-radiation as treatment in patients with stage III non-small cell lung cancer: A randomized phase II (RENO study). Isla D, De Las Peñas R, Insa A, Marsé R, Martínez-Banaclocha N, Mut P, Morán T, Sala MÁ, Massuti B, Ortega AL, Jurado JM, Gómez-Codina J, Diz P, Artal Á, Gutiérrez V, Vázquez MF, Viñolas N, Maestu I, Camps C, Álvarez R, de Mon Soto MÁ, Ponce S, Provencio M. Lung Cancer. 2019 Sep;135:161-168. doi: 10.1016/j.lungcan.2018.11.041. PMID: 31446990

Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cáncer. Argilés G, André T, Hollebecque A, Calvo A, Dahan L, Cervantes A, Leger C, Amellal N, Fougeray R, Tabernero J. European Journal of Cancer. 2019 May;112:12-19. doi: 10.1016/j.ejca.2019.01.101. PMID: 30889492

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors. Jung KH, LoRusso P, Burris H, Gordon M, Bang YJ, Hellmann MD, Cervantes A, de Olza MO, Marabelle A, Hodi FS, Ahn MJ, Emens LA, Barlesi F, Hamid O, Calvo E, McDermott D, Soliman H, Rhee I, Lin R, Pourmohamad T, Suchomel J, Tsuhako A, Morrissey K, Mahrus S, Morley R, Pirzkall A, Davis SL. Clinical Cancer Research. 2019 Jun 1;25(11):3220-3228. doi: 10.1158/1078-0432.CCR-18-2740.PMID: 30770348

Preclinical models for precision oncology (vol 1870, pg 239, 2018). Ibarrola-Villava M, Cervantes A, Bardelli A. Biochimica et Biophysica Acta-Reviews on Cancer. 2019 Dec;1872(2):188292. doi: 10.1016/j.bbcan.2019.05.002. PMID: 31138435

Prognostic Impact of pT Stage and Peritoneal Invasion in Locally Advanced Colon Cancer. Baguena G1, Pellino G1, Frasson M1, Roselló S2, Cervantes A2, García-Granero A1, Giner F3, García-Granero E. Diseases of the Colon & Rectum. 2019 Jun;62(6):684-693. doi: 10.1097/DCR.0000000000001367. PMID: 30839315

Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study. Ducreux M, Petersen LN, Öhler L, Bergamo F, Metges JP, de Groot JW, Wang JY, García Paredes B, Dochy E, Fiala-Buskies S, Cervantes A, O’Connor JM, Falcone A; CORRELATE Investigators. European Journal of Cancer. 2019 Dec;123:146-154. doi: 10.1016/j.ejca.2019.09.015. PMID: 31698328

Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial. Michels S, Massutí B, Schildhaus HU, Franklin J, Sebastian M, Felip E, Grohé C, Rodriguez-Abreu D, Abdulla DSY, Bischoff H, Brandts C, Carcereny E, Corral J, Dingemans AC, Pereira E, Fassunke J, Fischer RN, Gardizi M, Heukamp L, Insa A, Kron A, Menon R, Persigehl T, Reck M, Riedel R, Rothschild SI, Scheel AH, Scheffler M, Schmalz P, Smit EF, Limburg M, Provencio M, Karachaliou N, Merkelbach-Bruse S, Hellmich M, Nogova L, Büttner R, Rosell R, Wolf J. Journal of Thoracic Oncology. 2019 Jul;14(7):1266-1276. doi: 10.1016/j.jtho.2019.03.020. PMID: 30978502

SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018). Majem M, Juan O, Insa A, Reguart N, Trigo JM, Carcereny E, García-Campelo R, García Y, Guirado M, Provencio M. Clinical & Translational Oncology. 2019 Jan;21(1):3-17. doi: 10.1007/s12094-018-1978-1. PMID: 30446985

Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer. Tarazona N, Gimeno-Valiente F, Gambardella V, Zuñiga S, Rentero-Garrido P, Huerta M, Roselló S, Martinez-Ciarpaglini C, Carbonell-Asins JA, Carrasco F, Ferrer-Martínez A, Bruixola G, Fleitas T, Martín J, Tébar-Martínez R, Moro D, Castillo J, Espí A, Roda D, Cervantes A. Annals of Oncology. 2019 Nov 1;30(11):1804-1812. doi: 10.1093/annonc/mdz390. PMID: 31562764

The Medical Oncology resident mentor: situation and workload. Elez E, Quintanar T, Bosch-Barrera J, Corral J, Lainez N, Moreno V, Rodriguez CA, Gonzalez-Flores E, Cervantes A. Clinical & Translational Oncology. 2019 Mar;21(3):304-313. doi: 10.1007/s12094-018-1923-3. PMID: 30062521

Towards precision oncology for anti-HER2 blockade in gastroesophageal adenocarcinoma. Gambardella V, Fleitas T, Tarazona N, Cejalvo JM, Gimeno-Valiente F, Martinez-Ciarpaglini C, Huerta M, Roselló S, Castillo J, Roda D, Cervantes A. Annals of Oncology. 2019 Aug 1;30(8):1254-1264. doi: 10.1093/annonc/mdz143. PMID: 31046106

Transcriptomic metaanalyses of autistic brains reveals shared gene expression and biological pathway abnormalities with cáncer. Forés-Martos J, Catalá-López F, Sánchez-Valle J, Ibáñez K, Tejero H, Palma-Gudiel H, Climent J, Pancaldi V, Fañanás L, Arango C, Parellada M, Baudot A, Vogt D, Rubenstein JL, Valencia A, Tabarés-Seisdedos R. Molecular Autism. 2019 Apr 8;10:17. doi: 10.1186/s13229-019-0262-8. PMID: 31007884

Understanding mechanisms of primary resistance to checkpoint inhibitors will lead to precision immunotherapy of advanced gastric cáncer. Gambardella V, Fleitas T, Cervantes A. Annals of Oncology. 2019 Mar 1;30(3):351-352. doi: 10.1093/annonc/mdz008. PMID: 30657856

Understanding the clinical behavior of relapsed colon cancers with microsatellite instability relative to BRAF mutations. Roda D, Roselló S, Cervantes A. Annals of Oncology. 2019 Sep 1;30(9):1409-1410. doi: 10.1093/annonc/mdz229. PMID: 31350557

ZNF518B gene up-regulation promotes dissemination of tumour cells and is governed by epigenetic mechanisms in colorectal cancer. Gimeno-Valiente F, Riffo-Campos ÁL, Vallet-Sánchez A, Siscar-Lewin S, Gambardella V, Tarazona N, Cervantes A, Franco L, Castillo J, López-Rodas G. Scientific Reports. 2019 Jun 27;9(1):9339. doi: 10.1038/s41598-019-45411-9. PMID: 31249328